NASDAQ$TXMD
TherapeuticsMD Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter ended December 31, 2021.
TherapeuticsMD announced its Q4 2021 financial results, highlighting a definitive agreement to divest the vitaCare business unit and amended credit terms with Sixth Street. Demand for ANNOVERA continues to grow, and the company is focused on ensuring ample supply and access.
- Reached definitive agreement to fully divest vitaCare business unit.
- Amended credit terms with Sixth Street.
- ANNOVERA net product revenue decreased to $7.8 million.
- Net loss for the fourth quarter of 2021 was $43.0 million.
Headline financials
Revenue & EPS history
TherapeuticsMD · Revenue · Quarterly
$18.7M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+0.4%
Avg return
Earnings day
-1.0%
Avg return
5 days after
+0.9%
Avg return
30 days after
38%
24 / 64 earnings
Positive
+200.0%
Q1 2011
Best reaction
-27.5%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | -3.6% | -8.3% | +4.2% | |
| Q2 2025 | -0.9% | -2.7% | -1.8% | |
| Q1 2025 | -3.9% | -2.6% | -23.0% | |
| Q4 2024 | +6.1% | +20.9% | +26.1% | |
| Q3 2024 | -1.3% | -7.9% | -17.8% | |
| Q2 2024 | -1.2% | -4.0% | +2.9% | |
| Q1 2024 | +2.5% | +6.7% | -4.8% | |
| Q1 2026 | -1.9% | +6.7% | -4.8% | |
| Q4 2023 | +1.3% | -2.6% | -18.8% | |
| Q3 2023 | +17.1% | +12.4% | +18.3% | |
| Q2 2023 | -3.0% | -5.3% | -10.9% | |
| Q1 2023 | +0.2% | -1.6% | -13.9% | |
| Q4 2022 | +0.6% | +2.0% | +7.6% | |
| Q3 2022 | -15.0% | -27.8% | +0.3% | |
| Q2 2022 | +4.1% | +8.5% | -7.2% | |
| Q1 2022 | -12.1% | +1.0% | +223.1% | |
| Q4 2021 | -27.5% | -17.5% | -17.5% | |
| Q3 2021 | -12.5% | -18.1% | -37.5% | |
| Q2 2021 | -4.1% | -3.1% | -18.4% | |
| Q1 2021 | -14.8% | -18.7% | -5.5% | |
| Q4 2020 | +0.7% | -5.5% | -4.1% | |
| Q3 2020 | +10.7% | +0.8% | -4.9% | |
| Q2 2020 | -18.5% | -24.4% | -31.2% | |
| Q1 2020 | -5.8% | -5.8% | -15.1% | |
| Q4 2019 | -14.2% | -22.9% | -57.9% | |
| Q3 2019 | +4.1% | +5.2% | -10.3% | |
| Q2 2019 | +17.7% | +61.5% | +44.3% | |
| Q1 2019 | -12.8% | -20.9% | -26.8% | |
| Q4 2018 | -1.1% | +4.4% | -4.9% | |
| Q3 2018 | +6.0% | +0.4% | -3.4% | |
| Q2 2018 | -14.1% | -14.1% | +3.6% | |
| Q1 2018 | +2.2% | +4.9% | -0.7% | |
| Q4 2017 | -8.4% | -3.8% | -10.2% | |
| Q3 2017 | +27.8% | +30.0% | +33.0% | |
| Q2 2017 | -6.6% | -4.1% | +6.8% | |
| Q1 2017 | -6.4% | -6.8% | -12.2% | |
| Q4 2016 | +3.0% | +10.8% | +19.4% | |
| Q3 2016 | +0.0% | +10.5% | +19.7% | |
| Q2 2016 | +0.8% | +2.1% | -9.2% | |
| Q1 2016 | -5.8% | — | — | |
| Q4 2015 | +2.2% | — | — | |
| Q3 2015 | +2.2% | — | — | |
| Q2 2015 | -9.2% | — | — | |
| Q1 2015 | -11.6% | — | — | |
| Q4 2014 | +0.4% | — | — | |
| Q3 2014 | -15.3% | — | — | |
| Q2 2014 | +10.7% | — | — | |
| Q1 2014 | -9.0% | — | — | |
| Q4 2013 | +2.8% | — | — | |
| Q3 2013 | -10.0% | — | — | |
| Q2 2013 | -5.4% | — | — | |
| Q1 2013 | +0.4% | — | — | |
| Q4 2012 | -1.8% | — | — | |
| Q3 2012 | -8.7% | — | — | |
| Q2 2012 | +1.5% | — | — | |
| Q1 2012 | -2.0% | — | — | |
| Q4 2011 | -3.6% | — | — | |
| Q3 2011 | +0.0% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q1 2011 | +200.0% | — | — | |
| Q4 2010 | -25.0% | — | — | |
| Q3 2010 | +0.0% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q1 2010 | +0.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro